Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Impact · against what's priced in

The appointment of new lab providers and the quantification of the canine cancer screening TAM provide a concrete roadmap for revenue growth, though the overall market ceiling remains relatively low. This is incremental positive news for VNRX as it expands commercial reach in the U.S. and Asia.

VNRX+0.40

No priced-in read yet

In context

Expanding distribution via two new centralized labs in the U.S. and Asia increases the commercial reach for the Nu.Q® Vet Cancer test within a defined TAM of $100M to $150M.

Read from the article alone

• biotech▲12%
• healthcare
• VNRX
• animal health
• blood test
• cancer detection
• early detection
• epigenetics
• veterinary diagnostics